Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement aims for the commercialisation of HIPRA's mRNA COVID-19 vaccine, Bimervax, which combines a part of the SARS-CoV-2 virus spike protein with an adjuvant, in the United Kingdom.
Lead Product(s): Recombinant, Adjuvanted Covid-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Bimervax
Highest Development Status: ApprovedProduct Type: Vaccine
Recipient: Accord healthcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 04, 2023
Details:
Bimervax is a recombinant protein vaccine whose active substance is SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer – B.1.351-B.1.1.7 strains, it provides immune response at humoral and cellular level, against the COVID-19.
Lead Product(s): Recombinant Protein Covid-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Bimervax
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Veristat
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
Bimervax is a recombinant protein vaccine whose active substance is SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer – B.1.351-B.1.1.7 strains, it provides immune response at humoral and cellular level, against the COVID-19.
Lead Product(s): Recombinant Protein Covid-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Bimervax
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2023
Details:
Messenger RNA based Covid Vaccine is an adjuvanted recombinant protein vaccine based on a receptor-binding domain (RBD) fusion heterodimer containing variants alpha and beta of SARS-CoV-2 is authorized for phase III clinical trial.
Lead Product(s): Adjuvanted Recombinant Protein Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2022
Details:
The main objectives of the Phase IIb trial are to confirm safety and tolerability for a booster dose and to check if the booster dose prolongs the immune response to Covid-19 in people who have already been vaccinated.
Lead Product(s): Messenger RNA Based Covid Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2021